Safety and Efficacy Study of SOM230 s.c. in Cluster Headache

Condition:   Cluster Headache – Episodic and Chronic
Interventions:   Drug: SOM230;   Drug: Placebo;   Drug: Sumatriptan
Sponsor:   Novartis Pharmaceuticals
Recruiting – verified May 2017
Source: Listing of Cluster Headache trials
The purpose of this non-confirmatory study is to determine if SOM230 has adequate efficacy and safety to warrant further clinical development in cluster headache (CH). This study will have two parts. Part A will be a parallel design SOM230 vs. Placebo, and following an observed signal in Part A at an interim analysis, Part B of the study will be a comparison of SOM230 to sumatriptan.